Example: dental hygienist

注1、2) - jsts.gr.jp

TIA. 1 . 1-1.. 1 rt-PA . 3 . A .. rt-PA . 1 2 .. 2 t-PA desmoteplase . C2 . 3 . 60,000 / . 5 .. C1 . 1 rt-PA. 1 . 1 3 . 2 . 3 TIA 3 . 21 14 .. 185. mmHg 110mmHg 3.. 50mg/dL 400mg/dL 10 /mm . PT-INR APTT .. CT CT/MRI . 3 75 NIHSS 23 JCS100 . 10 3 .. 4 . a 24 . b . 48.. c /kg 10 . 1 2 1 . d . SCU 36 . 180mmHg 105mmHg . 24 .. CT MRI .. e . 1 . 15 . 1 7 30 . 7 24 1 . f . 2 15 . 2 8 30 . 8 24 1 . 180mmHg 105mmHg .. g .. 2 rt-PA 1 . 1 CT MRI 24 . 2 . SCU .. 3 . 4 .. 3 rt-PA . 2009 49. 1 . 2 . 3 b 1 . 3 5 . 6 . 3-6 . b The Cochrane stroke group 3. rt-PA 3 6 . 7 . 3 a . 8-10 .. 11 . a . rt-PA . 12 . 2008 9 3 rt- 13 . PA ECASS b.

50 脳卒中治療ガイドライン2009 51 6)Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator( Alteplase) for ischemic stroke 3 to 5 hours after

Tags:

  Stroke, Ischemic, Ischemic stroke

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of 注1、2) - jsts.gr.jp

1 TIA. 1 . 1-1.. 1 rt-PA . 3 . A .. rt-PA . 1 2 .. 2 t-PA desmoteplase . C2 . 3 . 60,000 / . 5 .. C1 . 1 rt-PA. 1 . 1 3 . 2 . 3 TIA 3 . 21 14 .. 185. mmHg 110mmHg 3.. 50mg/dL 400mg/dL 10 /mm . PT-INR APTT .. CT CT/MRI . 3 75 NIHSS 23 JCS100 . 10 3 .. 4 . a 24 . b . 48.. c /kg 10 . 1 2 1 . d . SCU 36 . 180mmHg 105mmHg . 24 .. CT MRI .. e . 1 . 15 . 1 7 30 . 7 24 1 . f . 2 15 . 2 8 30 . 8 24 1 . 180mmHg 105mmHg .. g .. 2 rt-PA 1 . 1 CT MRI 24 . 2 . SCU .. 3 . 4 .. 3 rt-PA . 2009 49. 1 . 2 . 3 b 1 . 3 5 . 6 . 3-6 . b The Cochrane stroke group 3. rt-PA 3 6 . 7 . 3 a . 8-10 .. 11 . a . rt-PA . 12 . 2008 9 3 rt- 13 . PA ECASS b.

2 2002 2003 3 . J-ACT . 14 . 2005 10 . J-ACT .. 60,000 / 7 5 . 15 . b .. 16-19 .. a .. rt-PA .. 1 rt-PA rt-PA. 2005 10 2005 27 327-354. 2 The National Institute of Neurological Disorders and stroke rt-PA stroke Study Group. Tissue plasminogen activator for acute ischemic stroke . N Engl J Med 1995 333 . 1581-1587. 3 Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke . The European Cooperative Acute stroke Study ECASS .JAMA 1995 274 1017-1025. 4 Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al.

3 Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke ECASS II . Second European-Australasian Acute stroke Study Investigators. Lancet 1998 352 1245-1251. 5 Clark WM, Albers GW, for the ATLANTIS stroke Study Investigators. The ATLANTIS. rt-PA Alteplase Acute stroke Trial nal results. stroke 1999 30 234. 50. 6 Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator Alteplase for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in ischemic stroke .

4 JAMA 1999 . 282 2019-2026. 7 Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke . Cochrane Database Syst Rev 2003 3 CD000213. 8 Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke the Standard Treatment with Alteplase to Reverse stroke STARS study. JAMA 2000 283 1145-1150. 9 Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke results of the Canadian Alteplase for stroke Effectiveness Study. CMAJ 2005 172 1307-1312. 10 Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in stroke - Monitoring Study SITS-MOST an observational study.

5 Lancet 2007 369 275-282. 11 Glenn GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice a meta-analysis of safety data. stroke 2003 34 2847-2850. 12 Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004 363 768-774. 13 Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to hours after acute ischemic stroke . N Engl J Med 2008 359 . 1317-1329. 14 Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al.

6 Alteplase at mg/kg for acute ischemic stroke within 3 hours of onset Japan Alteplase Clinical Trial J-ACT . stroke 2006 37 1810-1815. 15 . -Placebo - 1985 13 711-751. 16 Multicentre Acute stroke Trial--Italy MAST-I Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke . Lancet 1995 346 1509-1514. 17 Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, et al. Termination of trial of streptokinase in severe acute ischaemic stroke . MAST Study Group. Lancet 1995 345 . 57. 18 Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al.

7 Streptokinase for acute ischemic stroke with relationship to time of administration Australian Streptokinase ASK Trial Study Group. JAMA 1996 276 961-966. 19 The Multicenter Acute stroke Trial--Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke . N Engl J Med 1996 335 145-150. 2009 51.


Related search queries